(Q33347563)

26 July 2017

title

A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies (English)

1 reference

26 July 2017

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

25 December 2023

author name string

G. H. Schwartz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702533

25 December 2023

A. Patnaik

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702533

25 December 2023

L. A. Hammond

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702533

25 December 2023

J. Rizzo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702533

25 December 2023

K. Berg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702533

25 December 2023

D. D. Von Hoff

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702533

25 December 2023

E. K. Rowinsky

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702533

25 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12702533

25 December 2023

publication date

1 May 2003

1 reference

full work available at URL

26 July 2017

https://academic.oup.com/annonc/article-pdf/14/5/775/569424/mdg215.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702533

https://api.elsevier.com/content/article/PII:S0923753419635234?httpAccept=text/xml

25 December 2023

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

https://api.elsevier.com/content/article/PII:S0923753419635234?httpAccept=text/plain

25 December 2023

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

http://academic.oup.com/annonc/article-pdf/14/5/775/569424/mdg215.pdf

25 December 2023

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

25 December 2023

1 reference

26 July 2017

volume

14

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

775-782

1 reference

CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism

26 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

New antitumor substances of natural origin

25 December 2023

2

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065.

25 December 2023

3

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA

25 December 2023

4

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity

25 December 2023

7

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065

25 December 2023

9

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Phase I study of adozelesin (U-73,975) in patients with solid tumors

25 December 2023

10

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Phase I study of adozelesin administered by 24-hour continuous intravenous infusion

25 December 2023

11

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks

25 December 2023

12

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Phase I study with the DNA sequence-specific agent adozelesin

25 December 2023

13

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Phase II study of adozelesin in untreated metastatic breast cancer

25 December 2023

14

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule

25 December 2023

15

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).

25 December 2023

17

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines

25 December 2023

19

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

The genome factor in region-specific DNA damage: the DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level

25 December 2023

21

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

AT-rich islands in genomic DNA as a novel target for AT-specific DNA-reactive antitumor drugs

25 December 2023

22

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Region-specific DNA damage by AT-specific DNA-reactive drugs is predicted by drug binding specificity

25 December 2023

23

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Induction of AT-specific DNA-interstrand crosslinks by bizelesin in genomic and simian virus 40 DNA.

25 December 2023

24

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Effects of bizelesin (U-77,779), a bifunctional alkylating minor groove binder, on replication of genomic and simian virus 40 DNA in BSC-1 cells

25 December 2023

25

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Effects of bizelesin (U-77779), a bifunctional alkylating minor groove agent, on genomic and simian virus 40 DNA.

25 December 2023

26

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells

25 December 2023

27

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

Ligand-targeted therapeutics in anticancer therapy

25 December 2023

29

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG215

25 December 2023

Identifiers

1 reference

26 July 2017

1 reference